Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group

Giuseppe Procopio, Sandro Pignata, Amelia Altavilla, Laura Attademo, Delia De Lisi, Elena Verzoni, Ugo De Giorgi, Daniele Santini

Research output: Contribution to journalReview article

Abstract

Tyrosine kinase inhibitors still play a very important role in the treatment of metastatic renal cell carcinoma despite a continuously changing scenario, in which immunotherapy and several combination-based approaches are also available. In this light, patient-reported outcomes and health-related quality of life are important factors in the selection of the best first-line treatment. This Review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma.

Original languageEnglish
Pages (from-to)2657-2666
Number of pages10
JournalFuture Oncology
Volume15
Issue number22
DOIs
Publication statusPublished - Aug 1 2019

    Fingerprint

Keywords

  • mRCC
  • patient-reported outcomes
  • quality of life
  • TKIs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this